LL would be a great replacement for gsk hiv dolut
Post# of 148261
(Total Views: 780)
Posted On: 07/26/2022 3:38:04 PM
LL would be a great replacement for gsk hiv dolutegravir loses patent protection 2027
"There is also a need to find new treatments to fill the gap that will emerge as older products lose patent protection in the years ahead. The company will lose patent exclusivity on the HIV drug dolutegravir (worth about £3bn a year) at the end of 2027."
"There is also a need to find new treatments to fill the gap that will emerge as older products lose patent protection in the years ahead. The company will lose patent exclusivity on the HIV drug dolutegravir (worth about £3bn a year) at the end of 2027."
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼